Ergoteles’s CTI BioPharma Corp. (DE) Common Stock CTIC Stock Holding History

Ergoteles’s Portfolio CTIC Stock Details CTIC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-70,371	Closed	-$296K	–	1728
2023 Q1	$296K	Buy	+70,371	New	+$365K	0.01%	901

Other funds holding CTIC

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

Legal & General Group London, United Kingdom $432B AUM 29.4% 1-Year Est. Return

Ergoteles's CTIC Position: Q2 2023 in Review

Ergoteles sold out of CTI BioPharma Corp. (DE) Common Stock (CTIC) in Q2 2023, closing a stake of 70,371 shares — an estimated $296K sold.

Ergoteles first reported a position in CTIC in Q1 2023 and held it in 1 quarter. The position peaked at $296K in Q1 2023. 2 funds tracked by Wall St. Rank hold CTIC as of Q2 2023.

Ergoteles reported no remaining CTI BioPharma Corp. (DE) Common Stock position as of Q2 2023 after selling out during the quarter.
Ergoteles sold 70,371 CTI BioPharma Corp. (DE) Common Stock shares in Q2 2023, an estimated $296K.
Ergoteles first reported a position in CTI BioPharma Corp. (DE) Common Stock in Q1 2023 and held it in 1 quarter.
Ergoteles's CTI BioPharma Corp. (DE) Common Stock position peaked at $296K in Q1 2023.
2 funds tracked by Wall St. Rank held CTI BioPharma Corp. (DE) Common Stock as of Q2 2023.

Based on Ergoteles's 13F filing for Q2 2023, filed 14 Aug 2023.